ArticlePloS one2026
Carbapenem resistance and susceptibility to Ceftazidima/avibactam and Ceftolozane/tazobactam in Pseudomonas aeruginosa and Enterobacterales in a reference laboratory in Lima, Peru: A cross-sectional study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem resistance in Pseudomonas aeruginosa and Enterobacterales is a growing threat, with intrinsic and acquired resistance mechanisms resulting in the need for new therapeutic options. In Peru, data on resistance patterns and the effectiveness of new antibiotic combinations are limited A descriptive, cross-sectional, retrospective study was conducted on P. aeruginosa and Enterobacterales clinical isolates collected from 2019 to 2024 at a reference laboratory in Lima, Peru, originating from various public and private healthcare centers. Bacterial identification was performed using VITEK MS MALDI-TOF, and antimicrobial susceptibility testing via VITEK 2 and/or Kirby-Bauer disk diffusion. Carbapenemase production was detected using colorimetric, immunochromatographic, and molecular methods, including the FilmArray® BCID panel for bloodstream infections. Microbiological and epidemiological variables were analyzed with Poisson regression models. A total of 173,308 isolates were analyzed, with E. coli (74%) and K. pneumoniae (10.6%) being most prevalent. Most samples (92%) were urinary. Meropenem resistance in P. aeruginosa reached 33% overall and 60% in respiratory specimens. K. pneumoniae showed 3.4% carbapenem resistance. Among carbapenem-resistant isolates, 43.7% were carbapenemase producers. Carbapenemase production was highest in carbapenem-resistant K. pneumoniae (93.1%), E. coli (87.3%), and P. mirabilis (77.3%), but only 32.7% in P. aeruginosa. Among carbapenemase-producing Enterobacterales, metallo-β-lactamases predominated, with bla-NDM detected in 69.6% of K. pneumoniae and bla-OXA-48-like in 100% of E. coli. Ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) were highly active (>89%) against non-carbapenemase-producing P. aeruginosa, but <1% effective against producers. Resistance was more common in northern, eastern, and southern Lima. P. aeruginosa exhibited high carbapenem resistance, largely driven by non-carbapenemase mechanisms, supporting the role of C/T for treatment of non-carbapenemase-producing carbapenem-resistant P. aeruginosa. Among Enterobacterales, carbapenemase production was frequent in carbapenem-resistant isolates, with metallo-β-lactamases predominating. The limited activity of CZA against MBL producers underscores the urgent need for novel β-lactam/β-lactamase inhibitor combinations to address MBL-producing Enterobacterales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.